Paxlovid Useless In High Risk Patients Younger than 65 Years (Israeli Study)
If you like this content and want more, I am doing a special lifetime membership offer. Click here:
Want to support this work?:
Buy me a coffee 🙂 https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
My substack: https://mobeensyedmd.substack.com/
#drbeen #koolbeens #COVID
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.
URL list from Monday, Aug. 29 2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge | NEJM
Study: Pfizer COVID pill showed no benefit in younger adults – Los Angeles Times
Pfizer COVID pill provides little or no benefit in adults 40 to 65
Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis | Infectious Diseases | JAMA Network Open | JAMA Network